Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
27 February 2025 - 10:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
27
February 2025 - “Haleon Preliminary 2024 Full Year
Results”
|
|
|
|
99.1
Haleon plc: Preliminary 2024 Full Year Results
27 February 2025: Haleon plc (the "Company" or
"Haleon") (LSE/NYSE: HLN) today announces its preliminary full year
results statement for the year ended 31 December 2024 is available
at http://www.rns-pdf.londonstockexchange.com/rns/6119Y_1-2025-2-26.pdf.
The
preliminary full year results statement will also be available on
the Haleon website www.haleon.com/investors,
and the results have been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Dividend
Reflecting
the strength of free cash flow generation during the year,
alongside strong organic profit growth, the Board is proposing a
2024 total dividend of 6.6p per ordinary share which represents a
payout ratio of approximately 37% of 2024 adjusted earnings (2023:
35%). This includes a final dividend of 4.6p per ordinary
share.
Subject
to shareholder approval, the final dividend will be paid on 5 June
2025 to holders of ordinary shares and US American Depositary
Shares (ADS) on the register as of 25 April 2025 (the record date).
The ex-dividend date for ordinary shares is 24 April 2025 and for
US American Depositary Shares (ADS) is 25 April 2025. For ordinary
shareholders wishing to participate in the Dividend Reinvestment
Programme (DRIP), the election deadline is 15 May 2025. The DRIP is
provided by Equiniti Financial Services Limited, more information
is available at www.shareview.co.uk/info/drip.
Presentation for analysts and shareholders
A
recorded results presentation by Brian McNamara, Chief Executive
Officer, and Dawn Allen, Chief Financial Officer, will be available
shortly after 7am GMT (8am CET) on 27 February 2025 and can be
accessed at www.haleon.com/investors.
This will be followed by a Q&A session at 9am GMT (10am
CET).
For
analysts and shareholders wishing to ask questions on the Q&A
call, please use the dial-in details below which will have a
Q&A facility:
|
UK:
|
+44 (0)
800 358
1035
|
|
US:
|
+1 855
979 6654
|
|
All
other:
|
+44 (0)
203 936 2999
|
|
Passcode:
|
309530
|
An
archived webcast of the Q&A call will be available later on the
day of the results and can be accessed at www.haleon.com/investors.
This
information contains regulated information as per 6.3.7R of the
Disclosure and Transparency Rules of the Financial Conduct
Authority.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44
7894 505730
|
|
Emma
White
|
+44
7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon
(LSE/NYSE: HLN) is a global leader in consumer health, with a
purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For
more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
February 27, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (NYSE:HLN)
Historical Stock Chart
From Feb 2025 to Mar 2025
Haleon (NYSE:HLN)
Historical Stock Chart
From Mar 2024 to Mar 2025
